We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00285051
Recruitment Status : Suspended (Study drug expiry date not extended)
First Posted : February 1, 2006
Last Update Posted : April 28, 2017
Teva Branded Pharmaceutical Products, R&D Inc.
Information provided by:
Rafa Laboratories

Brief Summary:
Patients will be treated for 2 consecutive chemo cycles with the study drug for one and placebo for the other. In addition, patients will receive an injection before the chemo, either ondansetron (if receiving placebo inhalation) or normal saline) if receiving active study drug. They will take study medication for 3 days, 4 times daily and fill out VAS scores before and after doses. Patients will be given rescue medication with each dose.

Condition or disease Intervention/treatment Phase
Cancer Drug: inhaled delta-8-THC Phase 2

Detailed Description:

The study is comparing the use of inhaled delata-8-THC in the prevention of nausea and vomitting in patients being treated with moderately emetogenic chemotherapy, and the patients will continue use for 3 days afterward. Patients will be given rescue medication and will fill out VAS scales for nausea, pain, appetite and dizziness. Patients will be treated for 2 cycles, one cycle receiving active drug (one of 2 doses) and the other placebo. Patients receiving placebo will receive ondansetron injection before chemo and patients receiving active drug will receive a normal saline injection. Patients will take the drug 4 times daily for 3 days. The patients will return to clinic for a visit after 24-48 hours and 4 days. Patients will bring a urine sample to measure metabolite. Patients will be given a diary to monitor dosing and side effects as well as concomitant medication. The study will be conducted in 2 - 3 centers. There will be 108 patients enrolled with 27 in each of 4 groups:

Group 1 cycle 1 - Placebo cycle 2 - 300 mcg of delta-8-THC per dose Group 2 cycle 1 - Placebo cycle 2 - 600 mcg of delta-8-THC per dose Group 3 cycle 1 - 300 mcg of delta-8-THC per doseGroup cycle 2 - Placebo Group 4 cycle 1 - 600 mcg of delta-8-THC per dose cycle 2 - placebo

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 108 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Study to Compare the Safety and Efficacy of 2 Different Doses of Inhaled D8-THC to Standard Therapy With Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy
Study Start Date : November 2005
Estimated Study Completion Date : November 2005

Resource links provided by the National Library of Medicine

Drug Information available for: Ondansetron
U.S. FDA Resources

Primary Outcome Measures :
  1. VAS scale for nausea

Secondary Outcome Measures :
  1. No. of emesis
  2. VAS scale for delayed nausea
  3. VAS scale for pain
  4. VAS scale for appetite stimulation
  5. VAS scale for dizziness

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Signed informed consent
  • Man or woman between 18 and 85 years of age
  • Patients who will be receiving at least 2 more cycles of moderately emetogenic chemotherapy
  • Patients who are cognitively intact
  • Performance Status of 60% or greater on the Karnofsky Scale
  • Negative pregnancy test at screening visit in females of childbearing potential
  • Use of appropriate contraceptive methods for females of childbearing potential during treatment (e.g. hormonal contraception, intrauterine device [IUD])

Exclusion Criteria:

  • A history of psychiatric illness.
  • A history of asthma and any other chronic respiratory illness.
  • Subjects who, in the judgment of the investigator, are likely to be non-compliant or uncooperative during the study.
  • Serious illnesses such as asthma, diabetes mellitus, active peptic ulcer disease, infection, cardiovascular disease or any other disease which may affect the oucome parameters of this study
  • Abnormal liver function tests (ALT, AST or AP > 2.5 x upper normal limit)
  • Abnormal renal function (e.g. serum creatinine > 2 x upper normal limit)
  • Abnormal pulmonary function test which in the judgment of the investigator is incompatible with inhalation of the study drug
  • Known intolerance/hypersensitivity to study drugs (THC, ondansetron or dexamethasone) or drugs of similar chemical structure or pharmacological profile
  • History of addiction to alcohol or drugs
  • Existing or intended pregnancy or lactation
  • Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00285051

Shaare Zedek Medical Center
Jerusalem, Israel
Chaim Sheba Medical Center
Tel Hashomer, Israel
Sponsors and Collaborators
Rafa Laboratories
Teva Branded Pharmaceutical Products, R&D Inc.
Principal Investigator: Nathan Cherny, MD Shaare Zedek Medical Center, Dept. of Oncology

ClinicalTrials.gov Identifier: NCT00285051     History of Changes
Other Study ID Numbers: Rafa protocol THC002/NVP
First Posted: February 1, 2006    Key Record Dates
Last Update Posted: April 28, 2017
Last Verified: April 2017

Keywords provided by Rafa Laboratories:
emesis, nausea,

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Dermatologic Agents
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Anti-Anxiety Agents